A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes
| Autor: | Manoel Galvao Neto, Tarissa Petry, Bruno da Costa Martins, Paulo Sakai, Carlos A. Schiavon, José Luis Lopes Correa, Cristina Mamedio, João E. Salles, Ricardo Cohen, Christopher Sorli |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system diseases Adolescent Duodenum Endocrinology Diabetes and Metabolism Clinical Biochemistry Gastric Bypass Pilot Projects Type 2 diabetes medicine.disease_cause Biochemistry Body Mass Index Duodenal-jejunal bypass liner Endocrinology Internal medicine Diabetes mellitus Medicine Humans Prospective Studies Prospective cohort study Glycemic business.industry Gastric bypass surgery Biochemistry (medical) nutritional and metabolic diseases Middle Aged medicine.disease Obesity Glucose Jejunum Treatment Outcome Diabetes Mellitus Type 2 Female business Body mass index |
| Zdroj: | The Journal of clinical endocrinology and metabolism. 98(2) |
| ISSN: | 1945-7197 |
| Popis: | The duodenal-jejunal bypass liner (DJBL) is a device that mimics the intestinal portion of gastric bypass surgery and has been shown to improve glucose metabolism rapidly in obese subjects with type 2 diabetes (T2DM).To assess the safety of the DJBL and to evaluate its potential to affect glycemic control beneficially in subjects with T2DM who were not morbidly obese.Adult men and women with T2DM of ≤ 10 years' duration with hemoglobin A1c (HbA1c) ≥ 7.5% and ≤ 10% and having a body mass index ≥ 26 to ≤ 50 kg/m(2) were enrolled in this prospective, 52-week, single-center, open-label clinical study.Adverse events and changes in body weight, fasting plasma glucose (FPG) levels, and HbA1c levels.Sixteen of 20 subjects implanted with the DJBL completed the 1-year study (mean body mass index = 30.0 ± 3.6, mean ± SD). Gastrointestinal disorders were reported by 13 subjects, and metabolic or nutritional disorders occurred in 14 subjects. FPG levels dropped from 207 ± 61 mg/dL at baseline to 139 ± 37 mg/dL at 1 week and remained low throughout the study. Mean body weight also declined, but the change in body weight was not significantly associated with change in FPG at 52 weeks. HbA1c declined from 8.7 ± 0.9% at baseline to 7.5 ± 1.6% at week 52.The improvements in glycemic status were observed at 1 year in moderately obese subjects with T2DM, suggesting that the DJBL may represent an effective adjuvant to standard medical therapy of T2DM in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|